beta-adrenergic agonist resistance in normal human airways

Area of Science:

• Pharmacology
• Respiratory Medicine
• Clinical Investigation

Background:

• Beta2-agonists like salbutamol are standard treatments for reversible obstructive airways diseases.
• Understanding the mechanisms and potential tolerance to beta2-agonists is crucial for effective asthma management.
• Airways responsiveness can be quantified using specific airways conductance (sGaw).

Purpose of the Study:

• To investigate the development of beta-agonist resistance following regular high-dose inhaled salbutamol administration.
• To assess the impact of both inhaled and intravenous salbutamol on airways responsiveness.
• To determine if hydrocortisone can restore bronchodilator sensitivity in resistant subjects.

Main Methods:

• Healthy volunteers received increasing doses of inhaled or intravenous salbutamol.
• Specific airways conductance (sGaw) was measured to assess bronchodilator response.
• Beta-agonist resistance was induced by regular high-dose inhaled salbutamol ( > 200 microgram, 4 times daily).
• Hydrocortisone was administered intravenously to assess its effect on restored sensitivity.

Main Results:

• Regular high-dose inhaled salbutamol led to a progressive loss of airways responsiveness to subsequent salbutamol challenges (inhaled and intravenous).
• This phenomenon was termed 'beta-agonist resistance'.
• Intravenous hydrocortisone administration successfully restored full bronchodilator sensitivity in subjects who had developed resistance, within 3-5 hours.

Conclusions:

• Regular, high-dose use of inhaled salbutamol can induce clinically significant beta-agonist resistance in healthy individuals.
• Beta-agonist resistance is characterized by a diminished airways response to both inhaled and intravenous administration of the drug.
• Intravenous corticosteroids, such as hydrocortisone, are effective in reversing beta-agonist resistance and restoring airways responsiveness.